.Nature Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after an average consequence of 11 months, clients with metastatic stomach growths that acquired biomarker-matched therapies based upon flowing growth DNA profiling revealed a higher medical advantage than those acquiring incomparable therapy.